German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...
Hosted on MSN1mon
‘Where we are today in biology AI is similar to GPT in 2020’: An interview with the CEO of Africa’s biggest AI startupFifteen months on from completion of the BioNTech acquisition, co-founder and CEO Karim Beguir told TechCrunch in an interview that Instadeep has made significant progress on that front ...
Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...
Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...
Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
"We are already seeing the first signs of vaccine associated reduction of COVID-19 cases and mortality in multiple countries," said BioNTech CEO and co-founder Ugur Sahin. "We will continue to focus ...
Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...
Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “We remain focused on advancing our late-stage oncology product candidates towards potential registration. We believe our pipeline and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback